NCT05134350 is a Phase 1 clinical trial of LOXO-305 in Healthy Volunteers, sponsored by Loxo Oncology, Inc..

Who is sponsoring NCT05134350?

NCT05134350 is sponsored by Loxo Oncology, Inc..

What drugs are being tested in NCT05134350?

Interventions in NCT05134350: LOXO-305, Omeprazole.

What condition does NCT05134350 study?

NCT05134350 studies Healthy Volunteers.

Is NCT05134350 still recruiting?

NCT05134350 is currently completed. Last updated 10 January 2025.

Are results published for NCT05134350?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-01-10 · How we verify

NCT05134350

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants

Completed Phase 1 Results posted Last updated 10 January 2025

What this trial tests

Phase 1 trial testing LOXO-305 in Healthy Volunteers in 10 participants. Completed in 23 March 2020.

Timeline

6 February 2020

Primary endpoint
23 March 2020

23 March 2020

Quick facts

Lead sponsor	Loxo Oncology, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	10
Start date	6 February 2020
Primary completion	23 March 2020
Estimated completion	23 March 2020
Sites	1 location across United States

Drugs / interventions tested

LOXO-305 — full drug profile →
Omeprazole (omeprazole) — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Loxo Oncology, Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to learn about how food and a PPI (omeprazole) affect LOXO-305 in healthy participants. Participation could last about nine weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of LOXO-305

Trials testing the same drug.

NCT04849416 — A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) · Phase 2 · completed
NCT06180954 — A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants · Phase 1 · completed
NCT05134337 — Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Loxo Oncology, Inc. trials

Trials by the same sponsor.

NCT06104683 — A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis · Phase 2 · withdrawn
NCT05324124 — A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants · Phase 1 · completed
NCT05176314 — A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants · Phase 1 · completed
NCT05136404 — A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants · Phase 1 · completed
NCT05089019 — A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05134350 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Loxo Oncology, Inc.
Last refreshed: 10 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05134350.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing